Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir

Antiviral Therapy

Volumn 14, Issue 5, 2009, Pages 697-704

  Boivin, Guy ^a,b   Goyette, Nathalie ^a   Rollag, Halvor ^c   Jardine, Alan G ^d   Pescovitz, Mark D ^e   Asberg, Anders ^c   Ives, Jane ^f   Hartmann, Anders ^c   Humar, Atul ^g  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e INDIANA UNIVERSITY   (United States)

^f ROCHE PRODUCTS LTD   (United Kingdom)

^g UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; GANCICLOVIR; PROTEIN UL54; PROTEIN UL97; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS PROTEIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG HALF LIFE; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GRAFT RECIPIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; GANCICLOVIR; HUMANS; INJECTIONS, INTRAVENOUS; MUTATION; ORGAN TRANSPLANTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); TREATMENT OUTCOME; VIRAL PROTEINS;

EID: 69849110029     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fishman JA, Rubin RH. Infection In organ-transplant recipients. N Engl J Med 1998; 338:1741-1751.
2. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356:645-649.
3. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management In solid organ transplantation final report. Am J Transplant 2005; 5:218-227.
4. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption ol ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44:2811-2815.
5. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44:495-507.
6. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipientsL Am J Transplant 2007; 7:2106-2113.
7. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35:866-872.
8. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873-883.
9. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicentre study of solid-organ transplant recipients. J Infect Dis 2004; 189:1615-1618.
10. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytpmegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndroine who are receiving valganciclovir as induction and maintenance therapy for retinitis. J Infect Dis 2001; 184:1598-1602.
11. Martin M, Gilbert C, Covington E, Boivin G. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/ oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. J Infect Dis 2006; 194:579-583.
12. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002; 5:88-114.
13. Chou S, Lurain NS, Thompsop KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188:32-39.
14. Chou S, Lurain NS, Weinberg A, Cai GY, Sharma PL, Crumpacker CS. Interstrain variation in the human cytomegalovirus DNA polymerase seguence and its effect on genotypic diagnosis of antiviral drug resistance. Antimicrob Agents Chemother 1999; 43:1500-1502.
15. Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002; 185:162-169.
16. Fillet AM, Auray L, Alain S, et al. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved region located between domains delta-C II and betweem domains III and I. Antimicrob Agents Chemother 2004; 48:1865-1868.
17. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186:829-833.
18. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection amonp lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 1185:20-27.
19. Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytemegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002; 186:760-768.
20. Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir-resistant cytomegalovir in lung transplant recipients. J Heart Lung Transplant 2002; 21:1274-1282.
21. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytornegalovirus prevention in lung transplant recipients. Am J Transplant 2005; 5:1462-1468.
22. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000; 97:8039-8044.
23. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346:1119-1126.
24. Erice A, Gil-Roda C. Perez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175:1087-1092.
25. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176:69-77.
26. Chou S, Marousek GI, Van Wechel LC, Li S, Weinberg A. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 2007; 51:4160-4162.
27. Boivin G, Chou S, Quirk MR, Erice A, Jordan MC. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis 1996; 173:523-528.
28. Isada CM, Yen-Lieberman B, Lurain NS, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis 2002; 4:189-194.
29. Eckle T, Prix L, Jahn G, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000; 96:3286-3289.
30. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008; 46:831-839.
31. Boivin G, Goyette N, Gilbert C, Hurnar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005; 7:166-170.
32. Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007; 44:1315-1320.